AzTrials
AzTrials

Gestational Diabetes MellitusPhase 4DECIDENCT06445946

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

A Phase 4 study testing Metformin and Insulin in people with Gestational Diabetes Mellitus and Pregnancy, High Risk, run by Ohio State University at 26 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Metformin and Insulin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,572 participants
Where
26 sitesUnited States
Study dates
1 Aug 2024to Dec 2030
Phase
Phase 4

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Singleton gestation. Twin reduction to singleton, either spontaneously or therapeutically, is eligible if it occurred before 14 weeks gestational age.
  • Age 18 years or older
  • Gestational age at randomization between 20 0/7 - 33 6/7 weeks based on project gestational age.
  • GDM diagnosis less than or equal to 33 6/7 weeks based on project gestational age.
  • Requires medication for glucose control defined as ≥ 30% elevated glucose values (either fasting or postprandial or both) prior to randomization per determination of the provider or documented in the medical record.
  • Patient willingness and ability to attend 2-year follow-up visit.

Who cannot join

  • Renal disease (serum creatinine >1.3 mg/dL) due to the potential impact of metformin on renal function.
  • Major structural malformation of the fetus.
  • Known fetal aneuploidy based on invasive testing or positive for aneuploidy on cell-free fetal DNA screening.
  • Contraindication to metformin or insulin, including: history of lactic acidosis, intractable nausea and vomiting, prior documented allergy and/or anaphylaxis.
  • For individuals with GDM diagnosed <20 0/7 weeks, documented A1c ≥>6.5% within prior 6 months.
  • Pregestational diabetes documented in the medical record or prior A1c>= 6.5%
Show all 11Show fewer
  • Fasting hyperglycemia >115 mg/dl for ≥ 50% of fasting glucose values in the past week (due to the high risk of metformin failure with fasting hyperglycemia).
  • Enrolled in a trial that influences primary study outcomes (composite neonatal outcome at delivery or childhood body mass index at 2 years).
  • Prenatal care or delivery planned at a location where access to the complete electronic medical record will not be available to research staff.
  • Language barrier (appropriate translation resources unavailable at the site)
  • Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.

Trial locations and contacts

26 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Kartik Venkatesh, MD, PhD contact

614-293-2222

kartik.venkatesh@osumc.edu

Anna Bartholomew, MPH, BS, RN contact

614-685-3229

Anna.Bartholomew@osumc.edu

26 sites in 1 country

United States26 sites, 23 recruiting
  • University of New Mexico

    Albuquerque, New Mexico, 87131

    Vivek Katukuri, MD, vkatukuri@salud.unm.edu

    Karen Taylor, kataylor@salud.unm.edu

    Recruiting
  • University of Texas Austin

    Austin, Texas, 78705

    Lorie Harper, MD, lorie.harper@austin.utexas.edu

    Mickey Roberts, Mickey.roberts@austin.utexas.edu

    Recruiting
  • Austin Maternal Fetal Medicine

    Austin, Texas, 78758

    Mollie McDonnold, MD, 512-821-2540

    Heather Azarmehr, MSN, RN, 737-415-6210, Heather.Azarmehr@stdavids.com

    Recruiting
  • Tufts University

    Boston, Massachusetts, 02111

    Erika Werner, MD, erika.werner@tuftsmedicine.org

    Beth Marsh, Beth.Marsh@tuftsmedicine.org

    Recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

    Lydia Shook, MD, lshook@mgh.harvard.edu

    Nancy Kingori, nkingori@mgb.org

    Recruiting
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

    Terminated
  • University of North Caroline

    Chapel Hill, North Carolina, 27599

    Withdrawn
  • The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine

    Columbus, Ohio, 43210

    Kartik Venkatesh, MD, PhD, 614-293-2222, Kartik.Venkatesh@osumc.edu

    Kartik Venkatesh, MD, PhD

    Recruiting
  • Premier Health - Miami Valley Hospital

    Dayton, Ohio, 45409

    Samantha Wiegand, MD, slwiegand@premierhealth.com

    Emily Reynolds, ESReynolds@premierhealth.com

    Recruiting
  • University of South Carolina Greenville

    Greenville, South Carolina, 29605

    Kacey Eichelberger, MD, kacey.eichelberger@prismahealth.org

    Patti Parker, patti.parker@prismahealth.org

    Recruiting
  • University of Texas Health Science Center

    Houston, Texas, 77030

    Hector Mendez-Figueroa, MD, hector.mendezfigueroa@uth.tmc.edu

    Laura Nixon, Laura.Nixon@uth.tmc.edu

    Recruiting
  • Kettering Health

    Kettering, Ohio, 45429

    Hind Moussa, MD, 937-610-3220, Hind.Moussa@ketteringhealth.org

    Michelle Pershing, Michelle.Pershing@ketteringhealth.org

    Not yet recruiting
  • Cedars Sinai Medical Center

    Los Angeles, California, 90048

    Tania Esakoff, MD, Tania.esakoff@cshs.org

    Marla Sharp, Marla.Sharp@cshs.org

    Recruiting
  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226

    Anna Palatnik, MD, 414-955-2781, apalatnik@mcw.edu

    Alyssa Hernandez, DO, 414-955-2781, alyhernandez@mcw.edu

    Recruiting
  • Yale School of Medicine

    New Haven, Connecticut, 06520

    Tulin Ozcan, MD, 203-785-5855, tulin.ozcan@yale.edu

    Lauren Perley, MA, lauren.perley@yale.edu

    Recruiting
  • Columbia University Irving Medical Center

    New York, New York, 10032

    Noelia Zork, MD, nmz2110@cumc.columbia.edu

    Joseph Celentano, jmc2476@cumc.columbia.edu

    Recruiting
  • Christiana Care

    Newark, Delaware, 19718

    Withdrawn
  • Eastern Virginia Medical School - Old Dominion University

    Norfolk, Virginia, 23501

    Malgorzata Mlynarczyk, MD, mlynarm@evms.edu

    Cheryl Sparrer, SparreCD@evms.edu

    Recruiting
  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

    Celeste Durnwald, MD, 215-615-3817, Celeste.Durnwald@pennmedicine.upenn.edu

    Elizabeth Norton, MPH, MBE, 215-615-3817, Elizabeth.Norton@pennmedicine.upenn.edu

    Recruiting
  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213

    Maisa Feghali, MD, feghalim@mwri.magee.edu

    John Collins, collinsjn@mwri.magee.edu

    Recruiting
  • Brown University

    Providence, Rhode Island, 02912

    Martha Kole-White, MD, mkolewhite@kentri.org

    Kelsey Inglesby, KInglesby@Wihri.org

    Recruiting
  • University of California San Francisco

    San Francisco, California, 94143

    Nasim Sobhani, MD, Nasim.sobhani@ucsf.edu

    Magie Fong, magie.fong@ucsf.edu

    Recruiting
  • Washington University in St. Louis

    St Louis, Missouri, 63130

    Megan Lawlor, MD, lawlor@wustl.edu

    Emily Diveley, BSN, RN, 314-362-4685, diveley@wustl.edu

    Recruiting
  • University of South Florida

    Tampa, Florida, 33620

    Anjali Kaimal Kaimal, MD, akaimal@usf.edu

    Maha Jumaily, mahaaljumaily@usf.edu

    Recruiting
  • University of Alabama

    Tuscaloosa, Alabama, 35487

    Ashley Battarbee, MD, anbattarbee@uabmc.edu

    Michael Jordan, mejordan@uabmc.edu

    Recruiting
  • Wake Forest University

    Winston-Salem, North Carolina, 27106

    David Stamilio, MD, dstamili@wakehealth.edu

    Christina Tulbert, ctulbert@wakehealth.edu

    Recruiting

Other trials in United States

About this study

Official title: DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes

This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin.

This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.

Read the detailed description

Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. Glycemic control decreases the risk of adverse pregnancy outcomes for the pregnant individual with GDM and the infant exposed in utero (1). One in four individuals with GDM will require pharmacotherapy to achieve glycemic control. Insulin has been the mainstay of pharmacotherapy. Metformin is an alternative option increasingly used in clinical practice (2). Both insulin and metformin reduce the risk of adverse pregnancy outcomes, but comparative effectiveness data from a well-characterized, adequately powered, and diverse U.S. population remain lacking (3). Because metformin crosses the placenta, long-term safety data, in particular the risk of childhood obesity, from exposed children are also needed. In addition, the patient-reported experiences of individuals with GDM requiring pharmacotherapy remains to be characterized, including barriers for and facilitators of metformin versus insulin use.

In a two-arm open-label, pragmatic comparative effectiveness randomized controlled trial (RCT), the DECIDE Study will examine whether metformin is not inferior to insulin in reducing adverse pregnancy outcomes and is comparably safe for exposed mothers and children, and whether patient-reported factors, including facilitators of and barriers to use, differ between metformin versus insulin use. The DECIDE Study Consortium will recruit and retain 1,572 pregnant individuals with GDM who need pharmacotherapy at 20 U.S. sites to metformin versus insulin and follow them and their children through delivery and then to 2-years

Primary aim:

To evaluate whether outcomes in pregnant individuals randomized to metformin are not inferior to those in pregnant individuals randomized to insulin for the composite adverse neonatal outcome defined as large-for-gestational-age birthweight (LGA), hypoglycemia, hyperbilirubinemia, or death.

Secondary aims:

  1. To evaluate whether mean child body mass index (BMI) at 2 years of age is higher in the offspring of pregnant individuals randomized to metformin.
  2. To conduct a qualitative or mixed-methods analyses on a subgroup of participants to understand facilitators and barriers associated with metformin versus insulin use and heterogeneity of treatment effects (HTE) to facilitate evidence-based pharmacotherapy.
  3. To evaluate whether pregnant individuals randomized to metformin have equivalent maternal (hypertensive disorder of pregnancy, gestational weight gain, mode of delivery, and obstetric anal sphincter injuries) and neonatal (preterm birth, mechanical ventilation, NICU admission, oxygen support, and respiratory distress syndrome) outcomes.
  4. To evaluate whether pregnant individuals randomized to metformin have equivalent maternal (obesity, anthropometry, adiposity, diabetes, hypertension, cholesterol, and metabolic profile) and child (obesity, anthropometry, and adiposity) outcomes at 2-years postpartum.
  5. To evaluate whether pregnant individuals randomized to metformin have equivalent patient-reported outcomes (PROs), as measured at 6 weeks postpartum and at 2 years postpartum.
Being tested
Metformin, Insulin
Keywords
Insulin, Pregnancy, Glycemic control, Metformin, Gestational diabetes, Diabetes, Adverse pregnancy outcomes
Medical subject headings
Diabetes, Gestational, Insulin Resistance, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MetforminDrug

    Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.

  • InsulinDrug

    Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.

Study groups in NCT06445946
Study groupRoleWhat they receive
MetforminExperimentalMetformin as either immediate- or extended-release formulations can be utilized, and titrated to a maximum daily dose of 2,500 mg. Participants receiving metformin will have insulin added only if they have not achieved euglycemia for at least 30% of glucose values after generally receiving the maximum daily dose of metformin of 2,500 mg, or in select situations in the setting of participant intolerance due to mild gastrointestinal symptoms. Participants will be asked to continue taking metformin after treatment supplementation with insulin.
Receives: Drug: Metformin
InsulinExperimentalInsulin will be initiated utilizing clinical standards using trimester-specific weight-based dosing criteria, including both basal and prandial insulins for up to a total of 4 daily injections. Consistent with clinical practice, some people may be managed with a single dose of intermediate- or long-acting insulin at night to treat isolated fasting hyperglycemia, while others may require additional treatment of postprandial hyperglycemia with shorter-acting insulin. The sites' insulin formularies include rapid- (Novolog and Humalog), intermediate- (Humulin N, Novolin N, and NPH), and long-acting insulins (Detemir and Lantus).
Receives: Drug: Insulin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. A neonatal composite adverse outcome of large-for-gestational-age (LGA) birthweight, hypoglycemia, hyperbilirubinemia, and/or death.

    LGA will be defined as a birthweight ≥90th%tile for gestational age based on a US birth certificate reference adjusted for parity and/or fetal sex. Neonatal hypoglycemia will be defined as a blood glucose <35 mg/dL or treatment <24 hours after birth with either IV, PO, or gel glucose therapy. Neonatal hyperbilirubinemia will be defined as treated with phototherapy or exchange transfusion in the first postnatal week and either treatment in the first postnatal week or kernicterus. Fetal or neonatal death can be due to any indication between randomization to hospital discharge or 30 days postnatal if still hospitalized (excluding voluntary pregnancy termination).

    Measured: LGA at birth. Hypoglycemia <24 hours after birth. Hyperbilirubinemia within the first week after birth. Death between randomization to hospital discharge or 30 days postnatal.

  2. Child body mass index (BMI) at 2 years of age

    Child BMI measured in kg/m2 as a continuous measure standardized using U.S. CDC reference adjusted for child sex

    Measured: 2 years of age.

Secondary outcomes (26)
  1. Hypertensive disorder of pregnancy, HDP (maternal)

    HDP will include either gestational hypertension or preeclampsia. Gestational hypertension will be defined as: systolic blood pressure of 140 mm Hg or more or diastolic blood pressure of 90 mm Hg or more on two occasions at least 4 hours apart after 20 weeks of gestation in a woman with a previously normal blood pressure. Preeclampsia will be defined as: above blood pressure criteria AND proteinuria (300 mg or more per 24 hour urine collection, protein/creatinine ratio of 0.3 mg/dL or more, or dipstick reading of 2+) OR thrombocytopenia (platelet count less than 100 109/L), renal insufficiency (serum creatinine greater than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease), impaired liver function (elevated blood concentrations of liver transaminases to twice normal concentration), pulmonary edema, new-onset headache or visual symptoms not attributed to other diagnoses.

    Measured: Randomization to delivery

  2. Gestational weight gain (maternal)

    Gestational weight gain between weight at first prenatal visit and weight at delivery based on z-score and defined as excess versus within Institute of Medicine (IOM) recommendations based on first pregnancy BMI.

    Measured: Initiation of prenatal care to delivery

  3. Mode of delivery (maternal)

    Cesarean delivery or vaginal delivery

    Measured: At birth

  4. Obstetric perineal/anal sphincter injuries (maternal)

    First degree: Injury to perineal skin only; Second degree: Injury to perineum involving perineal muscles but not involving anal sphincter; Third degree: Injury to perineum involving anal sphincter complex, including 3a: Less than 50% of external anal sphincter thickness torn; 3b: More than 50% external anal sphincter thickness torn; and 3c: Both external anal sphincter and internal anal sphincter torn; and Fourth degree: Injury to perineum involving anal sphincter complex (external anal sphincter and internal anal sphincter) and anal epithelium.

    Measured: At birth

  5. Preterm birth (child)

    Preterm birth <37 weeks and <34 weeks based on project gestational age

    Measured: At birth

  6. Requiring mechanical ventilation (child)

    Intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula (HFNC) for ventilation or cardiopulmonary resuscitation within first 72 hours of birth

    Measured: <72 hours after birth

  7. NICU admission (child)

    Admitted to NICU or intermediate nursery ≥72 hours, any indication

    Measured: Birth to delivery discharge.

  8. Oxygen support (child)

    Requiring oxygen support

    Measured: <72 hours after birth

  9. Respiratory distress syndrome (child)

    Signs of respiratory distress with oxygen requirement and confirmed by chest x-ray.

    Measured: Anytime during the first 72 hours after birth

  10. Body mass index (BMI) (maternal)

    Continuous measure, using standardized protocol as kg/m2.

    Measured: 2-year follow-up

  11. Obesity overall and by class (maternal)

    BMI per the following classifications: Normal or underweight: < 25 kg/m2; Overweight: 25 to < 30 kg/m2; Class 1: 30 to < 35 kg/m2; Class 2: 35 to < 40 kg/m2; and Class 3: 40 kg/m2 or greater.

    Measured: 2-year follow-up

  12. Anthropometry (maternal)

    Waist circumference, continuous measures in cm

    Measured: 2-year follow-up

  13. Anthropometry (maternal)

    Hip circumference, continuous measures in cm

    Measured: 2-year follow-up

  14. Anthropometry (maternal)

    Waist - to - hip ratio, continuous measure

    Measured: 2-year follow-up

  15. Adiposity (maternal)

    Triceps, subscapular, suprailiac skinfolds, continuous measures in cm

    Measured: 2 year follow-up

  16. Type 2 diabetes (maternal)

    A1c > 6.5% OR fasting plasma glucose > 126 mg/dL OR OGTT > 200 mg/dL OR prior diagnosis per patient report

    Measured: 2-year follow-up.

  17. Prediabetes (maternal)

    A1c 5.7% to 6.4% OR fasting plasma glucose 100 mg/dl to 125 mg/dL OR OGTT 140 to 199 mg/dL

    Measured: 2-year follow-up.

  18. Hypertension (maternal)

    Per American Heart Association criteria as below and/or antihypertensive medication or prior diagnosis per patient report, and defined as: Elevated: Systolic between 120-129 and diastolic less than 80 mm Hg; Stage 1: Systolic between 130-139 or diastolic between 80-89 mm Hg; and Stage 2: Systolic at least 140 or diastolic at least 90 mm Hg.

    Measured: 2-year follow-up.

  19. Cholesterol (maternal)

    Fasting state, defined as a continuous measure and dichotomous at the following thresholds for each component: Total cholesterol: > 200 mg/dL; LDL cholesterol: > mg/dL; HDL cholesterol: < 40 mg/dL; Triglycerides: > 200 mg/dL.

    Measured: 2-year follow-up.

  20. Hemoglobin A1c (maternal)

    Continuous measure, percentage.

    Measured: 2-year follow-up.

  21. Overweight (child)

    BMI ≥85th%tile for age and sex.

    Measured: 2-year follow-up.

  22. Obesity (child)

    BMI ≥95th%tile for age and sex.

    Measured: 2-year follow-up.

  23. Anthropometry (child)

    Abdominal circumference; age- and sex-adjusted per WHO z-scores for arm circumference.

    Measured: 2-year follow-up.

  24. Adiposity (child)

    Triceps/subscapular skinfold thickness > 90th%tile for age and sex; individual and sum of measures.

    Measured: 2-year follow-up.

  25. Treatment Satisfaction Questionnaire for Medication (TSQM)

    The TSQM (version 1.4) comprises 14 items across four domains focusing on effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items) of the medication over the previous 2-3 weeks. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Item 4 was not included for scoring.

    Measured: 6-weeks postpartum.

  26. Questionnaire on Acceptability of Treatment

    A set of 5 questions developed in the Rowan et al. RCT assessing patient adherence, preferences, and experiences with metformin versus insulin for GDM (Rowan et al., NEJM, 2008).

    Measured: 6-weeks postpartum.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jun 2024
  2. Study start1 Aug 2024
  3. Primary completionDec 2029 (estimated)
  4. Study completionDec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,572 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06445946
Sponsor's protocol ID
2024H0193
Acronym
DECIDE
Status last verified
Oct 2026
First submitted
21 May 2024
Last updated
7 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: PCORI guidelines for data sharing will be followed, including the release of the Analyzable Data Set. This is the final cleaned and locked data set that contains all the data used in conducting the analyses reported in the PCORI Final Research Report and is de-identified in accordance with the HIPAA Privacy Rule.

Publications

  • Venkatesh KK, Chiang CW, Castillo WC, Battarbee AN, Donneyong M, Harper LM, Costantine M, Saade G, Werner EF, Boggess KA, Landon MB. Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study. BJOG. 2022 Feb;129(3):473-483. doi: 10.1111/1471-0528.16960. Epub 2021 Nov 8.

    PubMed 34605130
  • Venkatesh KK, Wu J, Trinh A, Cross S, Rice D, Powe CE, Brindle S, Andreatta S, Bartholomew A, MacPherson C, Costantine MM, Saade G, McAlearney AS, Grobman WA, Landon MB. Patient Priorities, Decisional Comfort, and Satisfaction with Metformin versus Insulin for the Treatment of Gestational Diabetes Mellitus. Am J Perinatol. 2024 May;41(S 01):e3170-e3182. doi: 10.1055/s-0043-1777334. Epub 2023 Dec 4.

    PubMed 38049101
  • Venkatesh KK, Lynch CD, Powe CE, Costantine MM, Thung SF, Gabbe SG, Grobman WA, Landon MB. Risk of Adverse Pregnancy Outcomes Among Pregnant Individuals With Gestational Diabetes by Race and Ethnicity in the United States, 2014-2020. JAMA. 2022 Apr 12;327(14):1356-1367. doi: 10.1001/jama.2022.3189.

    PubMed 35412565
  • Venkatesh KK, MacPherson C, Clifton RG, Powe CE, Bartholomew A, Gregory D, Trinh A, McAlearney AS, Fiechtner LG, Catalano P, Rice D, Cross S, Kutay H, Gabbe S, Grobman WA, Costantine MM, Battarbee AN, Boggess K, Katukuri V, Eichelberger K, Esakoff T, Feghali MN, Harper L, Kaimal A, Kole-White M, Mendez-Figueroa H, Mlynarczyk M, Sciscione A, Shook L, Sobhani NC, Stamilio DM, Werner E, Wiegand S, Zera CA, Zork NM, Saade G, Landon MB. Comparative effectiveness trial of metformin versus insulin for the treatment of gestational diabetes in the USA: clinical trial protocol for the multicentre DECIDE study. BMJ Open. 2024 Sep 24;14(9):e091176. doi: 10.1136/bmjopen-2024-091176.

    PubMed 39317491

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in